skip to Main Content

Our Science

Istari Oncology is committed to discovering and commercializing novel immunotherapies based on technology originally developed at Duke University in order to give hope to patients with cancer.

Our science is focused on our primary technology platform in clinical development, the Polio Virus Sabin-Rhinovirus Poliovirus (PVSRIPO). The results from multiple trials and preclinical research streams indicate that PVSRIPO has the potential to treat a variety of solid tumors that were previously thought of as untreatable. PVSRIPO’s versatility makes it a compelling lead therapeutic asset across glioblastoma tumors and anti-PD-1/L1 resistant melanomas.

Polio Virus Sabin-Rhinovirus Poliovirus (PVSRIPO)

Antibody Toxin Conjugates (ATCs)

News

Back To Top
×Close search
Search